{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.62","value":"80.3"},{"groupId":"OG001","spread":"10.72","value":"72.2"},{"groupId":"OG002","spread":"12.19","value":"74.4"}]}],"title":"Baseline (n=6, 6, 21)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.72","value":"79.2"},{"groupId":"OG001","spread":"10.01","value":"73.6"},{"groupId":"OG002","spread":"11.31","value":"74.2"}]}],"title":"Infusion (0 minutes) (n=6, 5, 19)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.41","value":"74.5"},{"groupId":"OG001","spread":"10.41","value":"69.5"},{"groupId":"OG002","spread":"11.87","value":"72.3"}]}],"title":"15 minutes post infusion (n=6,6,21)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.0","value":"78.8"},{"groupId":"OG001","spread":"10.29","value":"70.7"},{"groupId":"OG002","spread":"10.40","value":"71.1"}]}],"title":"30 minutes post infusion (n=6,6,21)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.67","value":"75.7"},{"groupId":"OG001","spread":"12.09","value":"69.8"},{"groupId":"OG002","spread":"12.69","value":"72.7"}]}],"title":"45 minutes post infusion (n=6,6,21)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.78","value":"78.7"},{"groupId":"OG001","spread":"9.97","value":"69.5"},{"groupId":"OG002","spread":"10.53","value":"74.1"}]}],"title":"60 minutes post infusion (n=6,6,21)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.20","value":"79.0"},{"groupId":"OG001","spread":"0.58","value":"71.7"},{"groupId":"OG002","spread":"11.93","value":"73.7"}]}],"title":"75 minutes post infusion (n=5,3,12)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.73","value":"79.8"},{"groupId":"OG001","spread":"8.18","value":"70.3"},{"groupId":"OG002","spread":"11.09","value":"74.4"}]}],"title":"90 minutes post infusion (n=4,4,14)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.58","value":"78.5"},{"groupId":"OG001","spread":"17.18","value":"74.4"},{"groupId":"OG002","spread":"10.24","value":"71.9"}]}],"title":"1 hour post infusion (n= 6,5,21)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.35","value":"83.0"},{"groupId":"OG001","spread":"19.04","value":"70.7"},{"groupId":"OG002","spread":"10.62","value":"72.0"}]}],"title":"2 hour post infusion (n= 6,6,21)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.20","value":"79.5"},{"groupId":"OG001","spread":"24.59","value":"67.8"},{"groupId":"OG002","spread":"11.98","value":"72.9"}]}],"title":"3 hour post infusion (n= 6,5,19)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.68","value":"75.2"},{"groupId":"OG001","spread":"13.64","value":"69.2"},{"groupId":"OG002","spread":"9.86","value":"73.5"}]}],"title":"4 hour post infusion (n= 6,6,21)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.81","value":"74.7"},{"groupId":"OG001","spread":"13.35","value":"77.7"},{"groupId":"OG002","spread":"10.32","value":"73.1"}]}],"title":"6 hour post infusion (n= 6,6,21)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.04","value":"83.8"},{"groupId":"OG001","spread":"15.29","value":"76.4"},{"groupId":"OG002","spread":"8.33","value":"74.7"}]}],"title":"8 hour post infusion (n= 5,5,21)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"21"}],"units":"Participants"}],"description":"Diastolic blood pressures (DBPs) measured in millimeters of mercury (mmHg) were obtained while the participant was seated. Baseline, Infusion (0 minutes) and Post infusion DBPs are presented in the 1 mg, 3 mg and 10 mg cohorts at: 15, 30, 45, 60, 75, and 90 minutes post infusion and at 1, 2, 3, 4, 6, 8 hours post infusion. Baseline was defined as the last measurement before the first dose of study drug, which was calculated from pre-dose or from screening if pre-dose was not available. Mean DBP on Day 1 for first dose (cycle 1) are presented below.","dispersionType":"Standard Deviation","groups":[{"description":"1 mg of nivolumab per kg of body weight was administered in a single IV infusion over 60 minutes on Day 1. Eligible participants could be re-treated and receive 2 more doses (1 dose every 4 weeks) at same dose as the single dose if: disease was stable, no drug intolerance was observed, no CR or PR was observed, or they had a positive immunogenicity sample within 4 weeks prior to re-treatment. Those who responded to therapy with a CR or PR were eligible for long-term follow-up until either PD or 2 years elapsed.","id":"OG000","title":"1 mg/kg Nivolumab"},{"description":"3 mg of nivolumab per kg of body weight was administered in a single IV infusion over 60 minutes on Day 1. Eligible participants could be re-treated and receive 2 more doses (1 dose every 4 weeks) at same dose as the single dose if: disease was stable, no drug intolerance was observed, no CR or PR was observed, or they had a positive immunogenicity sample within 4 weeks prior to re-treatment. Those who responded to therapy with a CR or PR were eligible for long-term follow-up until either PD or 2 years elapsed.","id":"OG001","title":"3 mg/kg Nivolumab"},{"description":"10 mg of nivolumab per kg of body weight was administered in a single IV infusion over 60 minutes on Day 1. Eligible participants could be re-treated and receive 2 more doses (1 dose every 4 weeks) at same dose as the single dose if: disease was stable, no drug intolerance was observed, no CR or PR was observed, or they had a positive immunogenicity sample within 4 weeks prior to re-treatment. Those who responded to therapy with a CR or PR were eligible for long-term follow-up until either PD or 2 years elapsed.","id":"OG002","title":"10 mg/kg Nivolumab"}],"paramType":"MEAN","populationDescription":"All participants who received at least 1 dose or any partial dose of nivolumab and had available blood pressure at baseline and post-infusion were analyzed.","reportingStatus":"POSTED","timeFrame":"Baseline, Day 1","title":"Mean Diastolic Blood Pressure at Baseline and Post-Infusion Day 1 (Cycle 1) in 1mg, 3mg, and 10 mg Cohorts - Safety Population","type":"SECONDARY","unitOfMeasure":"mmHg"}